Milly J McAllister1, Pamela McCall2, Ashley Dickson2, Mark A Underwood3, Ditte Andersen4, Elizabeth Holmes4, Elke Markert5, Hing Y Leung2,3,5, Joanne Edwards2. 1. Unit of Gastrointestinal Cancer and Molecular Pathology, Institute of Cancer Sciences, College of Medical, Veterinary, and Life Sciences, University of Glasgow, Glasgow, G61 1QH, UK. m.mcallister.1@research.gla.ac.uk. 2. Unit of Gastrointestinal Cancer and Molecular Pathology, Institute of Cancer Sciences, College of Medical, Veterinary, and Life Sciences, University of Glasgow, Glasgow, G61 1QH, UK. 3. Department of Urology, Queen Elizabeth University Hospital, Glasgow, G31 2ER, UK. 4. BioClavis Ltd, Glasgow, G51 4TF, UK. 5. Cancer Research UK Beatson Institute, Glasgow, G61 1BD, UK.
Abstract
BACKGROUND: Despite increases in diagnostics and effective treatments, over 300,000 men die from prostate cancer highlighting the need for specific and differentiating biomarkers. AR phosphorylation associates with castrate-resistance, with pARser213 promoting transcriptional activity. We hypothesise that combined pARser81 and pARser213 reduces survival and would benefit from dual-targeting androgen-dependent and Akt-driven disease. METHODS: Immunohistochemistry and immunofluorescence were performed on matched hormone-naive and castrate-resistant prostate cancer samples. TempO-Seq gene profiling was analysed using DESeq2 package. LNCaP-AI cells were stimulated with DHT or EGF. WST-1 assays were performed to determine effects of Enzalutamide and BKM120 on cell viability. RESULTS: Following the development of castrate-resistance, pARser81 expression reduced and pARser213 expression increased. Castrate-resistance pARser81 expression was not associated with survival but high pARser213 expression was associated with reduced survival from relapse. Combined high pARser81 and pARser213 was associated with reduced survival from relapse. pARser81 expression was induced by 10 nM DHT or 10 nM EGF and pARser213 expression was induced by treatment with 10 nM EGF in LNCaP-AI cells. Cell viability was reduced following treatment with 10 nM Enzalutamide and 10 nM BKM120. Eight genes were differentially expressed between hormone-naive and castrate-resistant tumours and twenty-five genes were differentially expressed between castrate-resistant tumours with high and low pARser213 expression. CONCLUSION: Combined pARser81 and pARser213 provides a novel prognostic biomarker for castrate-resistant disease and a potential predictive and therapeutic target for prostate cancer. Further studies will be required to investigate the combined effects of targeting AR and PI3K/AKT signalling.
BACKGROUND: Despite increases in diagnostics and effective treatments, over 300,000 men die from prostate cancer highlighting the need for specific and differentiating biomarkers. AR phosphorylation associates with castrate-resistance, with pARser213 promoting transcriptional activity. We hypothesise that combined pARser81 and pARser213 reduces survival and would benefit from dual-targeting androgen-dependent and Akt-driven disease. METHODS: Immunohistochemistry and immunofluorescence were performed on matched hormone-naive and castrate-resistant prostate cancer samples. TempO-Seq gene profiling was analysed using DESeq2 package. LNCaP-AI cells were stimulated with DHT or EGF. WST-1 assays were performed to determine effects of Enzalutamide and BKM120 on cell viability. RESULTS: Following the development of castrate-resistance, pARser81 expression reduced and pARser213 expression increased. Castrate-resistance pARser81 expression was not associated with survival but high pARser213 expression was associated with reduced survival from relapse. Combined high pARser81 and pARser213 was associated with reduced survival from relapse. pARser81 expression was induced by 10 nM DHT or 10 nM EGF and pARser213 expression was induced by treatment with 10 nM EGF in LNCaP-AI cells. Cell viability was reduced following treatment with 10 nM Enzalutamide and 10 nM BKM120. Eight genes were differentially expressed between hormone-naive and castrate-resistant tumours and twenty-five genes were differentially expressed between castrate-resistant tumours with high and low pARser213 expression. CONCLUSION: Combined pARser81 and pARser213 provides a novel prognostic biomarker for castrate-resistant disease and a potential predictive and therapeutic target for prostate cancer. Further studies will be required to investigate the combined effects of targeting AR and PI3K/AKT signalling.
Authors: John M S Bartlett; Daniella Brawley; Ken Grigor; Alison F Munro; Barbara Dunne; Joanne Edwards Journal: J Pathol Date: 2005-03 Impact factor: 7.996
Authors: Amy B Heimberger; Roman Hlatky; Dima Suki; David Yang; Jeff Weinberg; Mark Gilbert; Raymond Sawaya; Kenneth Aldape Journal: Clin Cancer Res Date: 2005-02-15 Impact factor: 12.531
Authors: Samantha Patek; Jennifer Willder; Jacob Heng; Bruce Taylor; Paul Horgan; Hing Leung; Mark Underwood; Joanne Edwards Journal: Oncotarget Date: 2017-01-17
Authors: J M Willder; S J Heng; P McCall; C E Adams; C Tannahill; G Fyffe; M Seywright; P G Horgan; H Y Leung; M A Underwood; J Edwards Journal: Br J Cancer Date: 2012-12-04 Impact factor: 7.640
Authors: Ying-Erh Chou; Po-Jen Yang; Chia-Yen Lin; Yen-Yu Chen; Whei-Ling Chiang; Pei-Xuan Lin; Zih-Yun Huang; Matthew Huang; Yung-Chuan Ho; Shun-Fa Yang Journal: Int J Environ Res Public Health Date: 2020-10-03 Impact factor: 3.390